Keywords: seattle, initiates, ph, ii, trial, scn-15, nsclc

Seattle initiates Ph II trial of SCN-15 in NSCLC

Article | 30 August 2001

Seattle Genetics has initiated a Phase II clinical trial whichcompares its monoclonal antibody conjugate SGN-15 plus Aventis' Taxotere (docetaxel) to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Aventis

Aventis Pharma

Go to company listing

Related Drugs

docetaxel

Taxotere

Go to drug listing